Metabolic and endocrinal effects of N-desmethyl-olanzapine in mice with obesity: Implication for...

Area of Science:

• Pharmacology
• Metabolic Research
• Endocrinology

Background:

• Clinical use of olanzapine (OLA) is linked to metabolic side effects.
• N-desmethyl-olanzapine (DMO) is a major OLA metabolite, but its metabolic role is unknown.
• Investigating DMO's impact on metabolic disturbance is crucial.

Purpose of the Study:

• To determine if DMO directly influences metabolic, endocrinal, and inflammatory parameters.
• To assess DMO's effects in a mouse model of diet-induced obesity.
• To compare DMO's metabolic profile with that of OLA.

Main Methods:

• Administration of DMO (2 mg/kg) to mice on a high-fat diet for 4 weeks.
• Evaluation of body weight, fat mass, insulin resistance, and energy expenditure.
• Analysis of lipid profiles, hepatic steatosis, white adipose tissue morphology, IL-1β production, and UCP1 expression.

Main Results:

• DMO administration led to significant body weight and fat mass reduction.
• Improved insulin resistance and increased energy expenditure were observed with DMO.
• DMO did not affect dyslipidemia or hepatic steatosis.
• White adipose tissue showed morphological changes, reduced IL-1β, and increased UCP1 expression.

Conclusions:

• DMO is devoid of the metabolic side effects commonly associated with OLA in obesity.
• N-desmethyl metabolism may play a regulatory role in OLA's metabolic responses.
• DMO presents a potential therapeutic avenue with a favorable metabolic profile.